Oncternal Therapeutics Value Stock - Dividend - Research Selection
Market price: 5,69 USD
Oncternal Therapeutics Inc Fundamental data and company key figures of the share
|Annual reports in USD|
|Net operating cash flow||-17.495.000|
|Free cash flow||-17.495.000|
|Liabilities & Shareholders equity||118.809.000|
|Diluted shares outstanding||20.310.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||115.563.904,00 USD|
|Raw Data Source||US GAAP in Millionen USD|
|Stock Split||2019-06-10,1.000000/7.000000; 2016-12-07,1.0000/10.0000; 2016-12-06,1.0000/10.0000|
Description of the company
GTx, Inc. is a biopharmaceutical company. The Company is developing selective androgen receptor modulators (SARMs) , a drugs with the potential to prevents and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). The Company is conducting the POWER 1 and POWER 2 (Prevention and treatment Of muscles Wasting in patients with cancER) pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer. In October 2012, it sold rights and related assets in the metastatic breast cancer product, Fareston, to ProStrakan Group plc.